कंपनी का अवलोकन
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical entity dedicated to the development and commercialization of biologic therapeutics designed to address life-threatening medical conditions. The company operates within the healthcare sector, specifically inside the biotechnology industry, which is characterized by high research and development expenditures and a focus on novel drug discovery. As of the latest available data, the organization maintains a market capitalization of $1.11 billion while reporting a trailing twelve-month revenue of $1.30 million and employing a workforce of 109 individuals. The valuation metrics suggest that the market places a significant premium on the company's intellectual property and pipeline potential, as evidenced by a market cap that is substantially higher than its current annual revenue generation, a common trait for clinical-stage firms that have not yet achieved commercial profitability but possess promising therapeutic candidates such as INBRX-109.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $1.30 million, yet it posted a net income of -$140,055,000, revealing a substantial divergence between top-line activity and bottom-line results that highlights an aggressive cost structure dominated by research, development, and operational expenses. This financial picture is further reinforced by an EBITDA of -$132,542,000, indicating that core operating activities are currently generating a loss rather than contributing to capital formation. Additionally, the free cash flow stands at -$84,456,128, which signifies that the company is burning through its available cash reserves to fund its growth initiatives and pipeline advancement. When analyzing profitability metrics, the gross margin is recorded at 0.0%, the operating margin is -10386.5%, and the profit margin is 0.0%, collectively demonstrating that the company is not yet generating positive returns on its sales or operations at this stage of development. Regarding balance sheet strength, the firm holds $124.22 million in cash against $107.01 million in debt, resulting in a debt-to-equity ratio of 1338.82, which points to a highly leveraged financial position relative to its equity base. Despite the high debt load, the current ratio of 3.93 indicates a robust level of short-term liquidity, suggesting the company possesses sufficient current assets to cover its current liabilities without immediate distress. Furthermore, the return on equity is -197.8% and the return on assets is -51.6%, metrics that reveal that management is currently unable to generate positive returns on the capital invested by shareholders or the assets owned by the firm.
मूल्यांकन आकलन
In terms of earnings-based valuation, the P/E ratio (TTM) is listed as N/A due to negative earnings, while the forward P/E stands at -27.15, implying that the market expects earnings to remain negative or for the company to continue operating at a loss in the near term. The price-to-book ratio is reported at 138.23, which indicates that the stock is trading at a massive premium compared to its book value, reflecting high investor expectations for future success despite current unprofitability. Alternative valuation multiples such as the price-to-sales ratio of 851.14 and the EV/EBITDA of -8.22 further illustrate that the market is pricing the company based on potential future value rather than current financial performance or cash flow generation. Price action analysis shows a 52-week high of $94.56 and a 52-week low of $10.80, providing a wide range of volatility within which the current trading price must be evaluated relative to these historical extremes. The beta value is listed as N/A, meaning that standard volatility measurements relative to the broader market index are not currently available for this specific security.
Growth & Income
The company's financial trajectory shows a revenue growth year-over-year of -100.0%, while earnings growth is marked as N/A, indicating that the business has likely transitioned from a revenue-generating phase or is in a period where commercial sales have ceased or not yet commenced. Since earnings growth is not applicable and revenue has contracted or is zero in this reporting context, the company is not in a growth phase driven by expanding sales but is instead focused on advancing its clinical pipeline before commercialization. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it retains all available funds to reinvest into its biologic therapeutics programs rather than distributing income to shareholders. Consequently, the overall growth and income profile of Inhibrx Biosciences, Inc. is defined entirely by its development of life-threatening condition treatments, with no current reliance on dividend income or organic revenue expansion.